GlobeNewswire·Apr 16, 2026, 7:25 AM ET

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that Daniel Claassen, M.D., M.S., its Chief Medical Advisor, will deliver an oral presentation at the American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.
The presentation, titled "ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale," is scheduled for Tuesday, April 21, 2026, at 6:21 PM CT during Late-Breaking Science 2.
The company is a clinical-stage biotechnology firm based in Melbourne, Australia, & San Francisco, California, focused on developing disease-modifying therapies for Multiple System Atrophy (MSA) & related Parkinsonian disorders.
ATH434, Alterity's lead asset, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial for MSA participants.
Alterity reported positive data from an open-label Phase 2 trial involving participants with advanced MSA.
The company is preparing to initiate a Phase 3 pivotal trial in MSA & maintains a broad drug discovery platform for treating neurological disease pathology.
The press release includes standard forward-looking statements & risk factors regarding drug development, regulatory approval, financing, & intellectual property.